Neoantigen × AI
Daily research signal
№56Brief

Small-molecule glues stabilize MHC-neoantigen complexes, preprint reports

Today's brief is a single methods signal: a preprint describing small-molecule 'peptide-MHC glues' that stabilize complexes between MHC class I and neoantigens that would otherwise go unpresented.bioRxiv

The relevance to the field is the addressable-antigen problem — a large share of predicted neoantigens never reach the cell surface, capping the usable target pool for vaccines and T-cell-directed therapies.bioRxiv Stage is early: compound discovery plus crystallography, with no cellular, animal, or clinical data described.bioRxiv

1new story
AI / MethodsyesterdayNew

Discovery of molecular glues for modulating MHC presentation of cancer neoantigens

A preprint reports the discovery of peptide-MHC glues (PMGs), compounds that promote formation of peptide-MHC class I complexes with cancer antigens that are otherwise poorly presented on the cell surface. Crystal structures of the complexes show the compounds stabilize antigen-MHC binding by making simultaneous interactions with both the MHC protein and the antigen peptide. The work targets a core bottleneck in neoantigen medicine: many cancer-specific antigens fail to form complexes with MHC-I, limiting the fraction usable for therapeutic targeting. As presented, this is early-stage chemical biology — discovery plus structural validation — with the implication that a chemical lever on antigen presentation could expand the targetable neoantigen space if it translates beyond structural studies.

biorxiv · yesterday · Shen, W.; Zhang, Z.; He, C.; Guiley, K. Z.; Lashkari, V. D.; Hernandez, J.; Bruno, P. M.;